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Abstract
Introduction:  The  incidence  of  cystic  ﬁbrosis  (CF)  in  Portugal  is  estimated  at  1:8000  live  births,
although there  is  a  lack  of  accurate  statistics.  The  average  life  expectancy  has  been  steadily
increasing and  CF  is  no  longer  an  exclusively  pediatric  disease.
Objectives:  Characterize  the  Portuguese  adult  population  with  the  diagnosis  of  CF.
Methods: Retrospective  study  based  on  clinical  data  of  adult  CF  follow-up  patients  in  the  three
specialized  centers  in  Portugal  where  all  of  CF  patients  are  seen,  during  2012.
Results:  In  2012,  there  were  89  follow-up  patients,  48  (54%)  female  and  15  (17%)  lung  trans-
planted. The  average  age  was  31.3  ±  9  years.  The  median  age  at  diagnosis  was  13  years  and  34
(38%) were  diagnosed  in  adulthood.  The  most  frequent  mutation  was  F508del  (54.9%).  Of  the  89
patients, 49  patients  (56%)  had  pancreatic  insufﬁciency,  7  (9%)  were  diabetic  and  42  patients
(47.7%) had  a  body  mass  index  (BMI)  <20  kg/m2.  As  to  ventilatory  function,  the  average  value
of the  forced  expiratory  volume  in  1  s  (FEV1)  was  58.45  ±  28.59%.  Only  one  of  77  patients  did
not have  chronic  airway  infection.  The  most  commonly  isolated  germ  was  methicillin-sensitive
Staphylococcus  aureus  in  49  patients  (55%).  During  2012,  two  patients  (2.2%)  died  at  the  ages
of 21  and  36  years.
Discussion:  This  study  is  the  ﬁrst  description  of  the  Portuguese  adult  CF  population,  which
is particularly  important  since  it  can  give  us  a  better  understanding  of  the  real  situation.  A
signiﬁcant percentage  of  these  patients  were  diagnosed  in  adulthood,  which  highlights  the  need
for diagnostic  suspicion  in  a  patient  with  chronic  lung  disease  and  atypical  manifestations.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).∗ Corresponding author.
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ntroduction
ystic  ﬁbrosis  (CF)  is  the  most  common  autosomal  recessive
onogenic  disease  in  the  Caucasian  population.  Its  inci-
ence  in  Portugal  is  estimated  at  1:8000  live  births,  based
n  preliminary  results  obtained  from  the  neonatal  screening
ilot  project,  ongoing  for  two  years.  This  pilot  project
ncountered  almost  only  F508del  homozygous,  therefore  its
rue  incidence  is  perhaps  underestimated.  However,  pre-
ise  statistical  data  does  not  exist.  In  all  28  European  Union
ountries,  the  prevalence  is  estimated  to  be  0.74  per  10,000
ndividuals.1 The  average  life  expectancy  has  been  steadily
ncreasing  and  CF  is  no  longer  an  exclusively  pediatric  dis-
ase,  affecting  more  adults  than  before.  In  the  1940s  to
960s  CF  was  usually  fatal  in  early  childhood  because  of
he  consequences  of  recurrent  pulmonary  infection  and
alnutrition  due  to  pancreatic  failure  and  subsequent  mal-
igestion  of  nutrients.  Initial  improvements  in  care  included
he  introduction  of  pancreatic  enzyme  replacement  therapy
n  the  1960s  and  enteric  coated  enzymes  in  the  early  1980s
o  treat  pancreatic  insufﬁciency  in  combination  with  a high
alorie  and  high  fat  diet.  Systemic  antibiotic  therapy  for  lung
nfection  and  the  development  and  use  of  inhaled  antibi-
tic  therapies  over  successive  decades  have  been  important
herapeutic  developments.  The  introduction  of  mucolytics
ncluding  dornase  alpha,  hypertonic  saline  and  more  effec-
ive  methods  of  airway  clearance  have  contributed  to  the
ajor  therapeutic  advances  from  the  1970s  to  the  current
ra.  These  and  other  supportive  therapies  for  complications
f  CF  have  been  delivered  by  multidisciplinary  teams  in
F  centers.  Centralized  care  with  dedicated  CF  teams  has
ecome  and  remains  the  cornerstone  of  care  delivery  in  CF.15
ccording  to  the  European  Cystic  Fibrosis  Society  patient
egistry  (ECFSPR)  data,  the  median  predicted  age  of  survival
t  2010  was  43.5  years  in  UK.2 In  Portugal  there  is  no  national
ata,  however,  according  to  CF  adult  follow-up  patients
n  specialized  centers,  the  average  age  is  30.7  years.3 In
ur  country  there  are  300  follow-up  patients  in  special-
zed  CF  outpatient  clinics  (less  than  expected  considering
he  incidence  in  Portugal),  and  approximately  one-third  are
dults.  In  this  group,  pulmonary  disease  tends  to  be  more
dvanced  and  associated  with  several  co-morbidities  such
s  diabetes,  metabolic  bone  disease,  cancer,  toxic  effects
nd  complications  associated  with  lung  transplantation.4
CF  is  caused  by  mutations  in  the  long  arm  of  chromosome
,  encoding  the  Cystic  Fibrosis  Transmembrane  Conductance
egulator  (CFTR),  which  is  expressed  predominantly  in  the
pithelial  cells.5 So  far  more  than  2000  mutations  have
een  identiﬁed,6 the  most  common  is  F508del  and  the  oth-
rs  are  rare.7 Mutations  in  this  gene  cause  changes  in  the
ransepithelial  ion  transport  of  chloride  and  the  organ  most
ffected  is  the  lung,  which  is  the  greatest  contributor  to  the
orbimortality.  It  results  in  impaired  mucociliary  clearance
nd  predisposition  to  airway  infection.5 Surprisingly,  infec-
ions  are  caused  by  a  limited  number  of  bacteria.  In  adults,
seudomonas  aeruginosa  and  Staphylococcus  aureus  are  the
ost  frequent  microorganisms.8 Recent  reports  document
n  increasing  incidence  of  new  Gram-negative  pathogens
uch  as  Stenotrophomonas  maltophilia,  Alcaligenes  xylosox-
dans  and  Burkholderia  cepacia  complex.9
u
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Even  when  aggressive  treatment  of  the  respiratory  dis-
ase  is  employed,  there  is  a  progressive  decline  in  lung
unction,  with  a  moderate-severe  impairment  present  in  60%
f  adults.10 When  lung  function  is  severely  compromised  lung
ransplantation  may  be  indicated.  In  these  patients,  bilat-
ral  lung  transplantation  is  the  only  option,  given  the  chronic
ronchial  infection.
The  disease  is  multisystemic  and  affects  all  organs  that
xpress  CFTR,  including  not  only  lung  but  also  pancreas,
ntestine,  biliary  tract,  vas  deferens,  sweat  and  salivary
lands.11
Exocrine  pancreatic  insufﬁciency  is  present  in  85%  of
atients  with  CF  and  the  clinical  manifestations  (such  as
teatorrhoea  and  poor  nutrition)  are  mostly  dealt  with
y  diet  and  pancreatic  enzyme  replacement.  In  some
atients  (8--15%),  as  time  progresses,  there  is  destruction
f  insulin-producing  cells,  resulting  in  endocrine  pancreatic
nsufﬁciency,  manifested  by  diabetes  mellitus.  Pancreatic
ufﬁciency  (15%)  may  be  present  at  an  older  age  and  usually
atients  have  milder  lung  disease  and  normal  or  borderline
weat  electrolyte  values.11
Usually  only  a  small  percentage  of  patients  (3--5%)  have
iver  disease,  which  manifests  clinically  as  neonatal  jaun-
ice,  hepatic  steatosis  or  biliary  cirrhosis.  It  is  also  possible
o  observe  a  micro-gallbladder  and  increased  incidence  of
allstones  (12%  of  patients),  which  normally  does  not  cause
ny  symptoms  and  does  not  require  treatment.11
Recurrent  constipation  and  distal  intestinal  obstruction
yndrome  (previously  known  as  meconium  ileus  equivalent)
re  features  in  older  patients  with  CF.11
Approximately  97%  of  males  with  CF  are  infertile  due  to
zoospermia  attributed  to  congenital  bilateral  absence  of
he  vas  deferens.  Infertility  may  be  the  initial  presentation
or  some  males  with  mild  disease.  However,  a  male  gender
F  patient  may  have  children,  by  puncturing  the  seminal
esicles,  doing  sperm  collection  and  in  vitro  fertilization.
n  the  female  gender  the  ovulation  is  normal,  but  given  the
dverse  conditions,  there  is  a  decrease  in  fertility  due  to
novulatory  cycles.  The  presence  of  thick  cervical  mucus,
hich  functions  as  a  barrier  to  sperm,  is  another  factor
ontributing  to  lower  fertility.11
Sweat  glands  in  CF  patients  do  not  show  any  histolog-
cal  abnormalities  but  have  pronounced  abnormalities  in
odium-chloride  homeostasis  due  to  defective  CFTR  func-
ion.  The  consequence  of  this  defect  is  a  resultant  sweat
ith  a  relatively  elevated  concentration  of  chloride  and
odium  compared  with  normal  sweat.  This  landmark  discov-
ry  led  to  the  development  of  the  sweat  test  for  diagnosis
n  1959.11 An  increased  concentration  of  electrolytes  in  the
weat  may  result  in  hyponatremic/hypochloremic  dehydra-
ion  secondary  to  salt  depletion  or  hypokalemic  metabolic
lkalosis  secondary  to  chronic  salt  loss.  Once  the  diagnosis
s  known  and  regular  salt  replacement  offered  this  problem
s  rarely  seen.11
Despite  the  technological  advances  in  recent  years,  in
erms  of  diagnostic  and  therapeutic  approach,  CF  remains  a
rogressive  and  lethal  chronic  disease.
This  study  aims  to  characterize  the  Portuguese  adult  pop-
lation  diagnosed  with  CF  followed  in  specialized  centers
uring  2012.
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Methods
Retrospective  analysis  based  on  clinical  data  of  adult  CF
follow-up  patients  in  the  three  specialized  centers  in  Portu-
gal  (Centro  Hospital  e  Universitário  de  Coimbra,  Centro  Hos-
pitalar  de  São  João, Porto  and  Centro  Hospitalar  de  Lisboa
Norte  --  Hospital  de  Santa  Maria, Lisbon,  Portugal),  where
all  of  CF  patients  are  seen,  in  2012.  The  following  varia-
bles  were  analyzed:  geographical  distribution,  gender,  age
(December  31st,  2012),  age  at  diagnosis,  mutations/CFTR
genotype,  nutritional  status,  pancreatic  function,  venti-
latory  function  (FEV1),  chronic  bronchial  infection,  lung
transplantation  and  mortality.  The  nutritional  status  was
evaluated  according  to  the  World  Health  Organization  and
classiﬁed  as  underweight  (BMI  <  18.5  kg/m2),  normal  weight
(BMI  18.5--24  kg/m2),  overweight  (BMI  26--39  kg/m2)  and
obesity  (BMI  >  30  kg/m2).12 The  severity  of  lung  disease  was
deﬁned  based  on  the  forced  expiratory  volume  in  1  s  (FEV1)
and  categorized  as  very  severe  (FEV1 ≤  20%),  severe  (FEV1
21--40%)  moderate  (FEV1 39--69%),  mild  (FEV1 89--70%)  and
normal  (FEV1 ≥  90).  Chronic  airway  infection  was  considered
if,  in  a  period  of  six  months,  three  or  more  positive  cultures
of  the  same  bacteria  were  isolated.  The  reference  ranges  of
sweat  test  by  the  conductivity  (semi-quantitative)  method
are  >90  mmol/L  if  positive  for  CF;  50--90  mmol/L  borderline
(could  be  CF);  <49  mmol/L  negative/normal.
Results
In  2012,  there  were  89  adult  follow-up  patients  with  FQ  were
in  Portugal,  42  at  the  Hospital  de  Santa  Maria,  in  Lisbon,
24  at  the  Centro  Hospitalar  e  Universitário  de  Coimbra-
Hospitais  da  Universidade  de  Coimbra  and  23  at  the  Centro
Hospitalar  de  São  João,  in  Porto.  Of  the  89  patients,  48  (54%)
were  female  and  41  (46%)  were  male  gender.  The  average
age  was  31.23  ±  9  years  (minimum  of  19  and  maximum  of
58  years).  The  age  distribution  was  mostly  between  23  and
27  years  (Chart  1).  The  age  at  diagnosis  ranged  from  two
months  to  58  years,  with  a  median  age  of  13  years,  and
34  (38%)  were  diagnosed  in  adulthood  (Chart  2).  The  sweat
test  was  positive  in  85  (94%)  patients,  borderline  in  four  (5%)
and  negative  in  one  patient  (1%).  The  genetic  study  of  the
CFTR  locus  was  done  for  all  patients.  The  most  frequent
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utation  was  F508del  in  95  patients  (54.9%),  27  patients
30%)  were  homozygotes  and  41  (46%)  heterozygous  for  this
utation.  The  second  most  frequent  mutation  was  R334W,
dentiﬁed  in  22  patients  (12.7%).  The  different  genotypes
nd  their  frequency  are  shown  in  Table  1. Of  the  89  patients,
9  (56%)  had  pancreatic  insufﬁciency  and  7  (9%)  were  dia-
etic.  Regarding  nutritional  status,  mean  body  mass  index
BMI)  was  20.93  ±  4.05  kg/m2, of  which  24  (27.3%)  were
nderweight,  54  (61.4%)  normal  weight,  8  (9.1%)  overweight
nd  2  (2.3%)  obese.  Of  the  77  patients  (excluding  patients
ransplanted  up  to  2011),  3  (3.9%)  had  very  severe  ventila-
ory  function,  15  (19.48%)  severe,  31  (40.26%)  moderate,  16
20.78%)  mild  and  12  (15.58%)  patients  had  normal  ventila-
ory  function.  The  average  FEV1 value  was  62.75  ±  27.84%,
ith  a  minimum  of  10.50%  and  a  maximum  of  133.90%.
onsidering  all  77  patients,  only  one  (1.3%)  did  not  have
hronic  airway  infection.  Of  the  patients  with  chronic  infec-
ion,  31  (40.3%)  had  only  one  microorganism  isolated  and
5  (58.4%)  had  more  than  two  microorganisms.  The  most
ommon  microorganism  was  methicillin-sensitive  S.  aureus
n  49  patients  and  Pseudomonas  aeruginosa  in  41  patients.
he  frequency  of  microorganisms  identiﬁed  is  shown  in  Chart
.  Of  the  patients  undergoing  lung  transplantation  (17%),  7
ere  female  and  8  male  gender.  The  average  survival  time
fter  lung  transplantation  was  3.53  ±  2.88  years,  with  a  min-
mum  of  one  year  and  a  maximum  of  eight  years.  During  2012
wo  female  patients  (2.2%)  died  at  21  and  36  years,  due  to
ung  transplant  rejection  and  sepsis  with  pulmonary  origin,
espectively.
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Table  1  Genotype  frequency.
Genotype  n  %  Genotype  n  %
F508del/F508del  27  30.3  F508del/del561E  1  1.1
F508del/R334W  9  10.3  F508del/G542X  1  1.1
F508del/P205S  5  5.6  F508del/I148N+IVS8-6(5T)  1  1.1
F508del/3272-26  A-G  4  4.5  F508del/I234W  1  1.1
F508del/G85E  3  3.4  F508del/R1066C  1  1.1
F508del/3272-26A>G  2  2.2  F508del/R334W/R1177E  1  1.1
F508del/IVS85T  2  2.2  F508del/V232D  1  1.1
F508del/L967S  2  2.2  F508del/2183  AA-G  1  1.1
F508del/R117H  2  2.2 F508del/NMI  2  2.2
F508del/3272/26  A-G 1  1.1 Other  heterozygous 21  23.6
F508del/A561E  1  1.1 Total 89  100
NMI: No mutation identiﬁed.
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his  study  is  the  ﬁrst  description  of  the  Portuguese  adult  CF
opulation,  which  is  particularly  important,  since  it  gives  a
etter  understanding  of  the  real  situation.  The  average  age
f  CF  patients  in  our  population  (31.23  ±  9  years)  reﬂects
he  increased  survival  in  this  pathology,  with  a  signiﬁcant
ercentage  of  patients  diagnosed  in  adulthood  (38%).13 New-
orn  screening  for  CF  started  as  a  pilot  project  in  Portugal  in
013  and  will  continue  until  the  end  of  2015.  This  screening
hen  implemented  in  other  European  countries  seems  to
revent  early  CF-related  deaths  and  leads  to  a  substantial
nd  prolonged  health  gain  for  patients  with  CF.7 This  study
ighlights  the  need  for  diagnostic  suspicion  in  a  patient  with
hronic  lung  disease  and  atypical  manifestations.  The  wide
eterogeneity  of  mutations  found  in  these  patients  complies
ith  that  described  in  South  Europe.14 Good  nutritional  sta-
us  and  reasonable  ventilatory  function  reﬂect  not  only  a
ide  spectrum  of  clinical  severity,  as  well  as  a  more  efﬁ-
ient  treatment  regime  and  very  regular  follow  up,  based
R
drganisms  frequency.
n  international  recommendations.  Therefore,  specialized
ollow  up  is  of  utmost  importance.
Lung  transplantation  is,  increasingly,  assumed  to  be
 therapeutic  alternative  in  the  later  stages  of  CF,  and
hese  patients  have  a  better  prognosis  if  they  have  this
ntervention.15
thical disclosures
rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
onﬁdentiality  of  data.  The  authors  declare  that  no  patient
ata  appear  in  this  article.ight  to  privacy  and  informed  consent.  The  authors
eclare  that  no  patient  data  appear  in  this  article.
ortu
1
1
1
1
1Cystic  ﬁbrosis  -  characterization  of  the  adult  population  in  P
Conﬂicts of interest
The  authors  have  no  conﬂicts  of  interest  to  declare.
References
1. Campbell P, Marshall B. Patient Registry 2013 Annual Data
Report. Cystic Fibrosis Foundation. 2014.
2. Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway
S. Report of the European Respiratory Society/European Cys-
tic Fibrosis Society task force on the care of adults with cystic
ﬁbrosis. Eur Respir J. 2016;47:420--8.
3. Pinto M, Pereira L, Rodrigues T, Barreto C. Cystic ﬁbrosis sur-
vival: the facts we can’t control. J Cyst Fibros. 2011;10:1--110.
4. Plant BJ, Goss CH, Plant WD, Bell SC. Management of comor-
bidities in older patients with cystic ﬁbrosis. Lancet Respir Med.
2013;1:164--74.
5. Jain M, Goss C. Update in cystic ﬁbrosis 2013. Am J Respir Crit
Care Med. 2014;189:1181--6.
6. Cystic Fibrosis Mutation Database. Available from: http://www.
genet.sickkids.on.ca/app.
7. Brice P, Jarret J, Mugford M. Genetic screening for cystic ﬁbro-
sis. An overview of the science and the economics. J Cystic
Fibros. 2007;6:255--61.
1gal  145
8. Santana M, Matos E, Fontoura M, Franco R, Barreto D, Lemos
A. Prevalence of pathogens in cystic ﬁbrosis patients in Bahia,
Brazil. Braz J Infect Dis. 2003;7:69--72.
9. Lambiase A, Raia V, Pezzo M, Sepe A, Carnovale V, Rossano F.
Microbiology of airway disease in a cohort of patients with cystic
ﬁbrosis. BMC Infect Dis. 2006;6:4.
0. Walters S, Mehta A. Epidemiology of cystic ﬁbrosis. In: Hodson
M, Geddes D, Bush A, editors. Cystic ﬁbrosis. 3rd ed. London:
Hodder Arnolds; 2007. p. 21--45.
1. Mishra A, Greaves R, Massie J. The relevance of sweat testing for
the diagnosis of cystic ﬁbrosis in the genomic era. Clin Biochem
Rev. 2005;26:135--53.
2. WHO. Global database on Body Mass Index an interactive surveil-
lance tool for monitoring nutrition transition. Available from:
http://apps.who.int/bmi/index.jsp?introPage=intro 3.html.
3. Pereira L, Bandeira T, Amaral MI, Barreto C. Aumento da
esperanc¸a média de vida nos doentes com ﬁbrose quística:
experiência do Centro de Fibrose Quística da Unidade de Pneu-
mologia do Servic¸o de Pediatria do Hospital de Santa Maria. Rev
Port Pneumol. 1998;4:599--609.
4. Estivill X, Bancells C, Ramos C. Geographic distribution and
regional origin of 272 cystic ﬁbrosis mutations in European popu-
lations. Hum Mutat. 1997;10:135--54.
5. Associac¸ão Nacional de Fibrose Quística, Available from:
www.anfq.pt/wpcontent/.  . ./Cromossoma7 n10.pdf.
